About   Help   FAQ
Phenotypes associated with this allele
Allele Symbol
Allele Name
Allele ID
Ifnar1tm1Pjh
targeted mutation 1, Paul J Hertzog
MGI:2667975
Summary 2 genotypes
Jump to Allelic Composition Genetic Background Genotype ID
hm1
Ifnar1tm1Pjh/Ifnar1tm1Pjh B6.129S2-Ifnar1tm1Pjh MGI:3776809
hm2
Ifnar1tm1Pjh/Ifnar1tm1Pjh involves: 129S2/SvPas * BALB/c MGI:2667989


Genotype
MGI:3776809
hm1
Allelic
Composition
Ifnar1tm1Pjh/Ifnar1tm1Pjh
Genetic
Background
B6.129S2-Ifnar1tm1Pjh
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Ifnar1tm1Pjh mutation (0 available); any Ifnar1 mutation (60 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
immune system
• the number of NK cells in the spleen is reduced by about a third compared to wild-type mice
• the ability of splenocytes to induce lysis of the NK target cells is reduced by half or more

neoplasm
• there is a 100% incidence of lymphoma after tumor cell transfer compared to only 9% incidence in wild-type mice
• 2- to 3- fold more mice develop fibrosarcomas 4 months after treatment with 3-methycholanthrene compared to wild-type controls

homeostasis/metabolism
• 2- to 3- fold more mice develop fibrosarcomas 4 months after treatment with 3-methycholanthrene compared to wild-type controls

hematopoietic system
• the number of NK cells in the spleen is reduced by about a third compared to wild-type mice
• the ability of splenocytes to induce lysis of the NK target cells is reduced by half or more




Genotype
MGI:2667989
hm2
Allelic
Composition
Ifnar1tm1Pjh/Ifnar1tm1Pjh
Genetic
Background
involves: 129S2/SvPas * BALB/c
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Ifnar1tm1Pjh mutation (0 available); any Ifnar1 mutation (60 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
mortality/aging
• following i.p. injection of EMCV at 10 times the TCID50, all neonatal homozygotes died suddenly within 38 hrs of inoculation, whereas all control mice had a mean survival time of ~60 hrs
• following i.p. injection of SFV at 100X the TCID50 on L cells, all neonatal homozygotes became moribund at 21 hrs after inoculation and died 3 hrs later, whereas wild-type and heterozygous controls showed a mean survival time of ~72 hrs

immune system
• homozygotes display increased levels of myeloid lineage cells in peripheral blood and bone marrow, as revealed by staining with Mac-1 and Gr-1 antibodies
• in response to graded low doses (80-625 ug/ml) of CSF-1, mutant bone marrow-derived macrophages (BMDMs) showed a significantly lower dose-dependent increase in thymidine incorporation than similarly-treated wild-type BMDMs; however, mutant BMDMs displayed a nearly normal proliferation in response to 5000 ug/ml of CSF-1
• mutant BMDMs were resistant to the antiproliferative effects of IFN-alpha (12.5-400 units/ml), whereas wild-type cells were inhibited by 95% in response to 12.5 units/ml and by 99% in response to higher IFN-alpha levels
• unlike wild-type BMDMs where LPS strongly inhibited CSF-1-stimulated thymidine incorporation, mutant BMDMs were resistant to the antiproliferative effects of LPS (100 ng/ml)
• in vitro, primary MEFs derived from E13 homozygous mutant embryos failed to exhibit protection against encephalomyocarditis virus (EMCV) infection by high levels of IFN-alpha or IFN-beta (>3000 units/ml), whereas wild-type MEFs were protected by levels as low as 3-58 units/ml
• following i.p. injection of EMCV at 10 times the TCID50, all neonatal homozygotes died suddenly within 38 hrs of inoculation, whereas all control mice had a mean survival time of ~60 hrs
• 24 hrs following i.p. injection of Semliki Forest virus (SFV at 100X the tissue culture 50% infective dose (TCID50) on L cells), viral titers of 104 to 1010 were detected in the lung, spleen, brain, liver and kidney of homozygous mutant mice, whereas no virus was detected in the organs of wild-type and heterozygous controls
• in vitro, primary MEFs derived from E13 homozygous mutant embryos failed to exhibit protection against SFV infection by high levels of IFN-alpha or IFN-beta (>3000 units/ml), whereas wild-type MEFs were protected by levels as low as 3-58 units/ml
• mutant BMDMs failed to develop an antiviral response to as high as 10,000 units/ml of IFN-alpha, whereas wild-type BMDMs showed a response to as little as 1 unit/ml of IFN-alpha
• in contrast, a similar IFN-gamma activity (~3 units/ml) was required to attain 50% inhibition of SFV-induced cytopathic effect in wild-type and mutant BMDMs
• following i.p. injection of SFV at 100X the TCID50 on L cells, all neonatal homozygotes became moribund at 21 hrs after inoculation and died 3 hrs later, whereas wild-type and heterozygous controls showed a mean survival time of ~72 hrs

hematopoietic system
• homozygotes display increased levels of myeloid lineage cells in peripheral blood and bone marrow, as revealed by staining with Mac-1 and Gr-1 antibodies
• in response to graded low doses (80-625 ug/ml) of CSF-1, mutant bone marrow-derived macrophages (BMDMs) showed a significantly lower dose-dependent increase in thymidine incorporation than similarly-treated wild-type BMDMs; however, mutant BMDMs displayed a nearly normal proliferation in response to 5000 ug/ml of CSF-1
• mutant BMDMs were resistant to the antiproliferative effects of IFN-alpha (12.5-400 units/ml), whereas wild-type cells were inhibited by 95% in response to 12.5 units/ml and by 99% in response to higher IFN-alpha levels
• unlike wild-type BMDMs where LPS strongly inhibited CSF-1-stimulated thymidine incorporation, mutant BMDMs were resistant to the antiproliferative effects of LPS (100 ng/ml)

homeostasis/metabolism
• basal levels of 2'-5' oligoadenylate synthetase (2'-5'OAS) activity in primary MEFs derived from E13 homozygous mutant embryos were severely reduced relative to those in wild-type and heterozygous MEFs (23 +/- 9 vs 189 +/- 54 and 130 +/- 64 pmol/ug of protein, respectively)
• unlike in wild-type MEFs, treatment with IFN-alpha or IFN-beta failed to induce 2'-5'OAS activity in homozygous mutant MEFs, indicating no signal transduction in response to type I IFNs





Contributing Projects:
Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB)), Gene Ontology (GO)
Citing These Resources
Funding Information
Warranty Disclaimer, Privacy Notice, Licensing, & Copyright
Send questions and comments to User Support.
last database update
12/10/2024
MGI 6.24
The Jackson Laboratory